Efficacy and Safety of Memantine in Patients With Mild to Moderate Vascular Dementia
- 1 July 2002
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Stroke
- Vol. 33 (7), 1834-1839
- https://doi.org/10.1161/01.str.0000020094.08790.49
Abstract
Based on the hypothesis of glutamate-induced neurotoxicity (excitotoxicity) in cerebral ischemia, this study examined the efficacy and tolerability of memantine, an uncompetitive N-methyl-D-aspartate antagonist, in the treatment of mild to moderate vascular dementia. In this multicenter, 28-week trial carried out in France, 321 patients received 10 mg/d memantine or placebo twice a day; 288 patients were valid for intent-to-treat analysis. Patients had to meet the criteria for probable vascular dementia and have a Mini-Mental State (MMSE) score between 12 and 20 at inclusion. The 2 primary end points were the cognitive subscale of the Alzheimers Disease Assessment Scale (ADAS-cog) and the global Clinician's Interview Based Impression of Change (CIBIC-plus). After 28 weeks, the mean ADAS-cog scores were significantly improved relative to placebo. In the intention-to-treat population, the memantine group mean score had gained an average of 0.4 points, whereas the placebo group mean score had declined by 1.6 points, ie, a difference of 2.0 points (95% confidence interval, 0.49 to 3.60). The response rate for CIBIC-plus, defined as improved or stable, was 60% with memantine compared with 52% with placebo (P=0.227, intention to treat). Among the secondary efficacy parameters, which were analyzed in the per-protocol subset, MMSE was significantly improved with memantine compared with deterioration with placebo (P=0.003). The Gottfries-Brane-Steen Scale intellectual function subscore and the Nurses' Observation Scale for Geriatric Patients disturbing behavior dimension also showed differences in favor of memantine (P=0.04 and P=0.07, respectively). Memantine was well tolerated with a frequency of adverse events comparable to placebo. In patients with mild to moderate vascular dementia, memantine 20 mg/d improved cognition consistently across different cognitive scales, with at least no deterioration in global functioning and behavior. It was devoid of concerning side effects.Keywords
This publication has 25 references indexed in Scilit:
- Evaluation of memantine for neuroprotection in dementiaExpert Opinion on Investigational Drugs, 2000
- A Prospective PMS Study to Validate the Sensitivity for Change of the D-Scale in Advanced Stages of Dementia Using the NMDA-Antagonist MemantinePharmacopsychiatry, 2000
- Differential effects of NMDA–receptor antagonists on long-term potentiation and hypoxic/hypoglycaemic excitotoxicity in hippocampal slicesNeuropharmacology, 2000
- Memantine is a clinically well tolerated N-methyl-d-aspartate (NMDA) receptor antagonist—a review of preclinical dataNeuropharmacology, 1999
- Psychotogenicity and N-methyl-D-aspartate receptor antagonism: Implications for neuroprotective pharmacotherapyBiological Psychiatry, 1997
- Effects of the Uncompetitive NMDA Receptor Antagonist Memantine on Hippocampal Long‐term Potentiation, Short‐term Exploratory Modulation and Spatial Memory in Awake, Freely Moving RatsEuropean Journal of Neuroscience, 1996
- Excitatory amino acids and Alzheimer's diseaseNeurobiology of Aging, 1989
- Clinical diagnosis of Alzheimer's diseaseNeurology, 1984
- GBS scaleArchives of Gerontology and Geriatrics, 1982
- “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinicianJournal of Psychiatric Research, 1975